Abstract | BACKGROUND: METHODS: From November 2001 to December 2007, 333 patients with hepatocellular carcinoma were treated with proton beam therapy at the University of Tsukuba. A total of 318 patients were included in this study. Total dose delivered and fractionation scheme were determined by protocols that varied based on location of tumor. Survival rates and prognostic factors were assessed. RESULTS: Overall actuarial survival rates at 1-year, 3-years, and 5-years were 89.5% (95% confidence interval [95% CI], 85.7-93.1%), 64.7% (95% CI, 56.6-72.9%), and 44.6% (95% CI, 29.7-59.5%), respectively. Child-Pugh liver function (hazards ratio [HR], 2.84; P < .01), T stage (HR, 1.94; P < .05), performance status (HR, 2.12; P < .01), and planning target volume (HR, 2.12; P < .05) significantly impacted survival. The 3-year and 5-year survival rates were 69.1% (95% CI, 59.9-78.3%) and 55.9% (95% CI, 41.5-70.3%), respectively, for patients with Child-Pugh A disease and 51.9% (95% CI, 32.3-71.5%) and 44.5% (95% CI, 23.1-65.8%), respectively, for patients with Child-Pugh B disease. The actuarial survival rates of patients with Child-Pugh class A were statistically different between groups of planned target volume <or=125 mL and >125 mL (P < .05). CONCLUSIONS:
|
Authors | Hidetsugu Nakayama, Shinji Sugahara, Mari Tokita, Kuniaki Fukuda, Masashi Mizumoto, Masato Abei, Junichi Shoda, Hideyuki Sakurai, Koji Tsuboi, Koichi Tokuuye |
Journal | Cancer
(Cancer)
Vol. 115
Issue 23
Pg. 5499-506
(Dec 01 2009)
ISSN: 0008-543X [Print] United States |
PMID | 19645024
(Publication Type: Evaluation Study, Journal Article)
|
Copyright | (c) 2009 American Cancer Society. |
Chemical References |
|
Topics |
- Aged
- Carcinoma, Hepatocellular
(mortality, radiotherapy)
- Female
- Humans
- Liver Neoplasms
(radiotherapy)
- Male
- Proton Therapy
- Radiotherapy Dosage
- Radiotherapy, Adjuvant
- Retrospective Studies
- Survival Rate
|